Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients.
about
Immunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous MelanomaPeripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma.PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?Liquid Biopsy and Therapeutic Targets: Present and Future Issues in Thoracic Oncology.Perspective on immune oncology with liquid biopsy, peripheral blood mononuclear cells, and microbiome with non-invasive biomarkers in cancer patients.PD-L1 immunohistochemistry for non-small cell lung carcinoma: which strategy should be adopted?Atezolizumab in advanced non-small cell lung cancer.Tumor-independent host secretomes induced by angiogenesis and immune-checkpoint inhibitors.Checkpoint blockade-based immunotherapy in the context of tumor microenvironment: Opportunities and challengesTip110/SART3 regulates IL-8 expression and predicts the clinical outcomes in melanomaBiomarkers for Immune Checkpoint Inhibitors in MelanomaAnti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination StrategiesAcquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanomaCan IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
P2860
Q42362520-7DB3C85F-F961-4A2C-ACDC-24C3D90C8D56Q46865924-5DF272CD-DE3E-4BFC-AE3A-305E394265FFQ47120629-058CE41D-AABB-43F4-8D8A-F64BEFA9CC2EQ47153925-A66FD8E1-7FEF-41A9-BD53-4C071F7ED4B6Q47219905-4ADE12FF-1860-4DB3-9292-49771378A787Q48620065-4D697AB3-1362-40CF-9E26-FBB0B075A6D7Q49259266-C31AE489-3A8A-4A6A-983F-607AF94A622CQ52562886-D1FC5264-41E4-427C-B9A2-8676954A8A2FQ57162847-3AE8B472-0B79-4A84-87B0-D61C903BCE64Q57168806-E374E0E2-1CEE-470F-B6F4-4925A8F2BAA8Q57175477-4317C595-B402-4A71-9CE1-3ECEBF789234Q58795231-739761E2-B54E-469A-AA02-BAB47DC8B6E8Q58796907-84AC6F0B-9F26-4C83-845B-5231D5568A3FQ58799410-90A1F7B9-BCE5-4E82-920F-EB87F77A91C2
P2860
Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Changes in serum interleukin-8 ...... all-cell lung cancer patients.
@en
Changes in serum interleukin-8
@nl
type
label
Changes in serum interleukin-8 ...... all-cell lung cancer patients.
@en
Changes in serum interleukin-8
@nl
prefLabel
Changes in serum interleukin-8 ...... all-cell lung cancer patients.
@en
Changes in serum interleukin-8
@nl
P2093
P2860
P50
P356
P1433
P1476
Changes in serum interleukin-8 ...... mall-cell lung cancer patients
@en
P2093
A Bacchiocchi
A Gonzalez
J L Perez-Gracia
K A Schalper
P2860
P304
P356
10.1093/ANNONC/MDX190
P577
2017-08-01T00:00:00Z